Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
AstraZeneca
Harvard Business School
Johnson and Johnson
Colorcon

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Saralasin acetate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for saralasin acetate and what is the scope of patent protection?

Saralasin acetate is the generic ingredient in one branded drug marketed by Procter And Gamble and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for saralasin acetate
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 5
Patent Applications: 5
DailyMed Link:saralasin acetate at DailyMed
Medical Subject Heading (MeSH) Categories for saralasin acetate
Synonyms for saralasin acetate
[Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate
[Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate, >=97% (HPLC), powder
34273-10-4 (Parent)
39698-78-7
CHEMBL1200670
D04126
FO21Z580M4
P-113
Saralasin acetate (USAN)
Saralasin acetate [USAN]
Sarenin
Sarenin (TN)
SCHEMBL2200145
UNII-FO21Z580M4

US Patents and Regulatory Information for saralasin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Procter And Gamble SARENIN saralasin acetate INJECTABLE;INJECTION 018009-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for saralasin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Procter And Gamble SARENIN saralasin acetate INJECTABLE;INJECTION 018009-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Procter And Gamble SARENIN saralasin acetate INJECTABLE;INJECTION 018009-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Johnson and Johnson
Harvard Business School
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.